Abstract
alpha-GalCer (also known as KRN7000) is an immunomodulatory glycolipid that is known to potently activate invariant natural killer T (NKT) cells upon CD1d-mediated stimulation. Because Th1 and Th2 cytokines, which are released after alpha-GalCer presentation, antagonize each other's effects, alpha-GalCer analogues that induce a biased Th1/Th2 response are highly awaited. In this context, we report the synthesis and in vitro evaluation of alpha-Gal-D-xylo-Cer and two alpha-Gal-L-lyxo-Cer analogues, one with the natural acyl chain, the other with a truncated chain.
Publication types
-
Evaluation Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antigens, CD1
-
Cytokines / immunology
-
Cytokines / metabolism
-
Galactosylceramides / chemical synthesis
-
Galactosylceramides / pharmacology*
-
Glycolipids / chemical synthesis
-
Glycolipids / pharmacology*
-
Killer Cells, Natural / drug effects*
-
Killer Cells, Natural / immunology
-
Killer Cells, Natural / metabolism
-
Mice
-
Mice, Inbred C57BL
-
Spleen / cytology
-
Spleen / drug effects*
-
Spleen / metabolism
-
Th1 Cells / drug effects*
-
Th1 Cells / immunology
-
Th1 Cells / metabolism
-
Th2 Cells / drug effects*
-
Th2 Cells / immunology
-
Th2 Cells / metabolism
Substances
-
Antigens, CD1
-
Cytokines
-
Galactosylceramides
-
Glycolipids
-
alpha-galactosylceramide
-
KRN 7000